| Oncolytics Biotech Inc. announced that it has closed its previously announced $12.75M offering in which a syndicate of underwriters purchased 4.25M units of the Company, each unit comprised of one common share and 0.4 of a common share purchase warrant, at a price of $3.00 per unit. Each whole common share purchase warrant entitles the holder to acquire one common share of Oncolytics upon payment of $3.50 for a five year period commencing on the closing date of the offering, subject to an acceleration of the expiry date in certain circumstances. Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. Canaccord Capital Corporation and Bloom Burton & Co. acted as Canadian co-managers for the offering. The Company has granted the underwriters an over-allotment option to purchase additional common shares and/or warrants in an amount up to 15%. Oncolytics intends to use the net proceeds from the offering to fund its previously announced Phase III combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers, its other clinical development and research and development activities, and for general corporate and working capital purposes. :theflyonthewall.com |
